Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2000
10/19/2000WO2000062071A1 Diagnostic and therapeutic use of antibodies against the urokinase receptor
10/19/2000WO2000062067A1 Novel transduction molecules and methods for using same
10/19/2000WO2000061788A2 Poly(dipeptide) as a drug carrier
10/19/2000WO2000061757A1 Tumor necrosis factor homologs and nucleic acids encoding the same
10/19/2000WO2000061726A1 Composition for the preservation of infectious recombinant adenoviruses
10/19/2000WO2000061668A1 Preparing porous hydrogel products
10/19/2000WO2000061616A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
10/19/2000WO2000061577A1 Prodrugs of thrombin inhibitors
10/19/2000WO2000061543A2 Esters of l-carnitine or alkanoyl l-carnitines
10/19/2000WO2000061204A1 Three-dimensional stromal tissue
10/19/2000WO2000061192A2 Methods and compositions for the treatment of pancreatitis
10/19/2000WO2000061191A2 Heat stable coated colloidal iron oxides
10/19/2000WO2000061190A2 Treatment of intracellular infection
10/19/2000WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds
10/19/2000WO2000061183A2 Verotoxin treatment of lymphomas
10/19/2000WO2000061177A1 Composition based on oppositely-charged polypeptides
10/19/2000WO2000061175A2 Use of pegylated interferon alpha in melanoma therapy
10/19/2000WO2000061174A2 Use of pegylated interferon alpha for renal cell carcinoma treatment
10/19/2000WO2000061170A2 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid)
10/19/2000WO2000061169A1 Pharmaceutical compositions of erythropoietin
10/19/2000WO2000061168A1 Ocular treatment using cyclosporin-a derivatives
10/19/2000WO2000061156A2 Methods of treating schizophrenia
10/19/2000WO2000061149A1 Long-acting antibacterial composition
10/19/2000WO2000061147A1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
10/19/2000WO2000061132A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000WO2000061121A2 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy
10/19/2000WO2000061120A1 Preparations for percutaneous absorption
10/19/2000WO2000061117A1 Fast-dispersing dosage forms containing fish gelatin
10/19/2000WO2000061116A2 Pharmaceutical formulation comprising amoxycillin and clavulanate
10/19/2000WO2000061115A2 Pharmaceutical formulation comprising amoxycillin
10/19/2000WO2000061114A1 Fine particles targeting cells and process for producing the same
10/19/2000WO2000061113A1 Lipid aggregate forming compositions and their uses
10/19/2000WO2000061112A2 Solubilized pharmaceutical composition for parenteral administration
10/19/2000WO2000061111A1 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
10/19/2000WO2000061110A1 Icecream-type pharmaceutical formulation and process for preparing the same
10/19/2000WO2000061106A1 Antimicrobial wipes which provide improved immediate germ reduction
10/19/2000WO2000061104A1 Cosmetic preparations
10/19/2000WO2000061102A1 Cosmetic and/or pharmaceutical preparations
10/19/2000WO2000061078A2 Sunscreen agents containing hydroxycarboxylic acid alkyl- and/or -alkenyloligoglycoside esters
10/19/2000WO2000060956A1 Hydrogel-forming system with hydrophobic and hydrophilic components
10/19/2000WO2000060953A2 Methods for stabilizing liquid nutritional products and products so stabilized
10/19/2000WO2000049991A3 Treatment of trauma
10/19/2000WO2000042992A3 Compositions and methods for mucosal delivery
10/19/2000WO2000039290A8 Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid
10/19/2000WO2000037103A3 Compounds for intracellular delivery of therapeutic moieties to nerve cells
10/19/2000WO2000034296A3 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
10/19/2000WO2000032626A8 Methods of using epitope peptides of human pathogens
10/19/2000WO2000024437A3 Textured and porous silicone rubber
10/19/2000WO2000023022A8 Method and compositions for in situ formation of protective and/or medicated films on body tissue
10/19/2000DE19916211A1 Kosmetische und/oder pharmazeutische Zubereitungen Cosmetic and / or pharmaceutical preparations
10/19/2000DE19916210A1 Kosmetische Zubereitungen Cosmetic preparations
10/19/2000DE19916208A1 Sonnenschutzmittel Sunscreens
10/19/2000CA2382628A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000CA2372078A1 Treatment of intracellular infection
10/19/2000CA2369684A1 Novel method of treatment
10/19/2000CA2369472A1 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid)
10/19/2000CA2369439A1 Methods of treating schizophrenia
10/19/2000CA2369262A1 Pulmonary administration of dry powder formulations for treating infertility
10/19/2000CA2369096A1 Use of increased-molecular-weight hirudin as an anticoagulant in extracorporeal kidney replacement therapy
10/19/2000CA2369029A1 Poly(dipeptide) as a drug carrier
10/19/2000CA2369012A1 Preparations for percutaneous absorption
10/19/2000CA2368830A1 Prodrugs of thrombin inhibitors
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/19/2000CA2364690A1 Novel transduction molecules and methods for using same
10/19/2000CA2364659A1 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
10/19/2000CA2364570A1 Preparing porous hydrogel products
10/19/2000CA2364562A1 Composition for the preservation of infectious recombinant adenoviruses
10/19/2000CA2364536A1 Fragments of virus protein 2 or 3 of polyoma virus, as vehicules for active substances
10/19/2000CA2305942A1 Composition containing at least one aromatic bicyclic compound and at least one 2-alkyl alcan-1-ol or an ester, and its uses
10/18/2000EP1045000A1 Cellulose ether films
10/18/2000EP1044691A2 Use of glycosaminoglycan lipid conjugates for inducing osteogenesis
10/18/2000EP1044689A1 Solid iodophor preparations and process for producing the same
10/18/2000EP1044688A1 Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparations containing pyridonecarboxylic acid and process for producing the same
10/18/2000EP1044687A1 Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same
10/18/2000EP1044686A1 Alcoholic coloured chlorhexidine solution and its manufacturing process
10/18/2000EP1044683A1 One-step dispersion method for the microencapsulation of water soluble substances
10/18/2000EP1044682A1 Process for producing hard capsule
10/18/2000EP1044680A1 Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate
10/18/2000EP1044678A1 Lacrimal gland specific emulsions for topical application to ocular tissue
10/18/2000EP1044218A1 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
10/18/2000EP1044197A2 New piperidinyl-substituted pyridylalkane, alkene and alkine carboxamides
10/18/2000EP1044023A1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
10/18/2000EP1044022A2 Compositions and methods for targeted delivery of factors
10/18/2000EP1044021A1 Enhanced transport using membrane disruptive agents
10/18/2000EP1044016A1 Stabilised insulin compositions
10/18/2000EP1044015A1 Formulations for amylin agonist peptides
10/18/2000EP1044013A2 Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
10/18/2000EP1044005A1 1,2,4-benzotriazine oxides formulations
10/18/2000EP1043997A1 A dried or frozen pharmaceutical preparation containing a class iii antiarrhythmic compound
10/18/2000EP1043986A2 Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
10/18/2000EP1043985A1 Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
10/18/2000EP1043984A1 Pharmaceutical compositions containing bupropion hydrochloride and an inorganic acid stabilizer
10/18/2000EP1043979A1 Compositions for the transdermal and dermal administration of biologically active agents
10/18/2000EP1043978A1 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
10/18/2000EP1043976A1 Oral pharmaceutical extended release dosage form
10/18/2000EP1043973A1 Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
10/18/2000EP1043963A1 Osteopontin-based compositions for enhancing bone repair
10/18/2000EP1043941A1 Revitalisation formulation
10/18/2000EP0921793B1 Solid, non-deliquescent formulations of sodium valproate
10/18/2000EP0885393A4 Graphitic nanotubes in luminescence assays
1 ... 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 ... 1712